Anavex Life Sciences (AVXL)
(Real Time Quote from BATS)
$4.47 USD
-0.04 (-0.89%)
Updated Jul 9, 2024 01:22 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Brokerage Reports
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 81 - 100 ( 156 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: DSMB - Alzheimer''s Study Should Continue: No Change
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Alzheimer''s Disease Phase 2/3 Trial Continuation Recommended; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: We See ANAVEX2-73 as an Undervalued Asset in the CNS Space ? Alzheimer''s, Raising Our Price Target to $19.00 from $16.00
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
F1Q21 Financial Results; Lengthy Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Recent Stock Appreciation May Portend Further Value Inflection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Fiscal 2020 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Positive Phase 2 Rett Syndrome Data; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Recent Patent Allowance Could Extend Exclusivity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Phase 2 Parkinson''s Disease Data Indicates Path Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Positive Phase 2 Parkinson''s Disease Data; Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Anavex2-73 Phase 2 Trial Demonstrates Proof of Concept
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Parkinson''s Dementia Data Imminent; F3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Second Pipeline Candidate Enters Clinical Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Excellent. Anavex2-73 Enrolls First Phase 2/3 Patient in Rett Syndrome (EXCELLENCE) Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Anavex2-73 Exceeds Enrollment Target in Rett Syndrome Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Enrollment Target Substantially Exceeded in Rett Syndrome Phase 2 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Alzheimer''s Disease Trial Geographic Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
ANAVEX?3-71 Enters First-in-Human Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R